Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
29274307
DOI
10.1016/j.amjmed.2017.11.042
PII: S0002-9343(17)31277-9
Knihovny.cz E-resources
- Keywords
- Anticoagulants, Cancer, Low-molecular-weight heparin, Thromboembolism, Warfarin,
- MeSH
- Anticoagulants administration & dosage MeSH
- Heparin, Low-Molecular-Weight administration & dosage MeSH
- Humans MeSH
- Neoplasms complications MeSH
- Recurrence MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Propensity Score MeSH
- Vitamin K antagonists & inhibitors MeSH
- Venous Thromboembolism drug therapy etiology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anticoagulants MeSH
- Heparin, Low-Molecular-Weight MeSH
- Vitamin K MeSH
BACKGROUND: Low-molecular-weight heparin (LMWH) is the treatment of choice in cancer patients with venous thromboembolism. However, data on continuing LMWH treatment beyond 6 months remain scanty. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the rate of venous thromboembolism recurrences and major bleeding appearing beyond the first 6 months of anticoagulant therapy in cancer patients with venous thromboembolism, according to therapy with LMWH or vitamin K antagonists (VKA). We performed a propensity score-matched cohort study. RESULTS: After propensity matching, 482 cancer patients continued to receive LMWH and 482 switched to VKA. During the course of anticoagulant therapy (mean 275.5 days), 57 patients developed venous thrombosis recurrences (recurrent pulmonary embolism 26, recurrent deep vein thrombosis 29, both 2), 28 had major bleeding, 38 had nonmajor bleeding, and 129 died. No patient died of recurrent venous thrombosis, and 5 patients died of bleeding (2 were on LMWH, 3 on VKA). Patients who continued with LMWH had a similar rate of deep vein thrombosis recurrences (relative risk [RR] 1.41; 95% confidence interval [CI], 0.68-2.93), pulmonary embolism recurrences (RR 0.73; 95% CI, 0.34-1.58), major bleeding (RR 0.96; 95% CI, 0.51-1.79), or nonmajor bleeding (RR 1.15; 95% CI, 0.55-2.40), compared with those who switched to VKA, but a higher mortality rate (RR 1.58; 95% CI, 1.13-2.20). CONCLUSIONS: In cancer patients with venous thromboembolism who completed 6 months of LMWH therapy, switching to VKA was associated with a similar risk of venous thrombosis recurrences or bleeding when compared with patients who continued LMWH.
Department of Internal Medicine Hospital General Virgen de la Luz Cuenca Spain
Department of Internal Medicine Hospital Universitario La Paz Madrid Spain
Department of Internal Medicine Ospedale S Maria della Misericordia Udine Italy
Department of Médecine et Thérapeutique Hôpital Nord CHU St Etienne Saint Etienne France
Department of Medicine McMaster University Hamilton ON Canada
Department of Pneumonology Hospital General Universitario Gregorio Marañón Madrid Spain
Intensive Care Unit Hospital Clínica La Merced Quito Ecuador
References provided by Crossref.org